Related Experiment Videos
[Coxibs: cyclooxygenase-2 inhibitors].
1Institut für Pharmakologie, Universität Wien, Osterreich. klaus.turnheim@univie.c.at
Wiener Klinische Wochenschrift
|September 27, 2001
Summary
Cyclooxygenase (COX) exists in two forms, COX-1 and COX-2. Selective COX-2 inhibitors offer pain relief with fewer stomach issues, but kidney risks remain similar to traditional NSAIDs.
Area of Science:
- Biochemistry
- Enzymology
Context:
- Cyclooxygenase (COX) enzymes catalyze prostaglandin synthesis, crucial for inflammation and physiological processes.
- Initially considered a single enzyme, COX activity was later found to be inducible in inflammatory states.
Purpose:
- To differentiate between cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoforms.
- To understand the distinct roles of COX-1 and COX-2 in physiological and pathological conditions.
- To evaluate the therapeutic potential and limitations of selective COX-2 inhibitors.
Summary:
- COX-1 is constitutively expressed, maintaining gastric protection, kidney function, and platelet aggregation.
- COX-2 is inducible, mediating inflammation, fever, and pain, but also involved in kidney regulation.
- Conventional NSAIDs inhibit both COX-1 and COX-2, causing therapeutic effects via COX-2 and side effects via COX-1.
- Selective COX-2 inhibitors (e.g., celecoxib, rofecoxib) provide similar pain relief with reduced gastroduodenal toxicity but comparable renal toxicity.
Impact:
- Distinguishing COX isoforms clarifies their roles in health and disease.
- Development of selective COX-2 inhibitors offers improved gastrointestinal safety profiles for anti-inflammatory and analgesic therapies.
- Highlights the need for continued research into managing the renal side effects of NSAIDs and selective COX-2 inhibitors.